Adoptive immunotherapy of Cytokine-induced killer cell therapy in the treatment of Non-small cell lung cancer

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Wang, Min ^a   Cao, Jun Xia ^a   Pan, Jian Hong ^b   Liu, Yi Shan ^a   Xu, Bei Lei ^a   Li, Duo ^a   Zhang, Xiao Yan ^a   Li, Jun Li ^a   Liu, Jin Long ^a   Wang, Hai Bo ^a   Wang, Zheng Xu ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CYTOKINE INDUCED KILLER CELL THERAPY; FEVER; HUMAN; META ANALYSIS; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; TREATMENT RESPONSE; BIOLOGICAL THERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINE INDUCED KILLER CELL; IMMUNOLOGY; LUNG NEOPLASMS; MULTIMODALITY CANCER THERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; TRANSPLANTATION; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CELL- AND TISSUE-BASED THERAPY; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84911917654     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112662     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics. CA Cancer J Clin 55: 74-108.
2. Chen WQ, Zheng RS, Zhang SW, Zhao P, Li GG, et al. (2013) Chinese cancer registration annual report: National cancer registration center of lung cancer. Chin J Cancer Res 25(1): 10-21.
3. Arango BA, Castrellon AB, Santos ES, Raez LE (2009) Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer 10(2): 91-98.
4. National Institutes of Health (2012) Cancer of the Lung and Bronchus-SEER Stat Facts Sheet. http://seer.cancer.gov/statfacts/htm/lungb.html.
5. Jiang J, Liang X, Zhou X, Huang R, Chu Z, et al. (2013) Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. J Cancer Res Clin Oncol 139(1): 25-38.
6. Wu C, Jiang J, Shi L, Xu N (2008) Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28(6B): 3997-4002.
7. Choi D, Kim TG, Sung YC (2012) The past, present, and future of adoptive T cell therapy. Immune Netw 12(4): 139-147.
8. Sangiolo D (2011) Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2: 363-368.
9. Rutella S, Iudicone P, Bonanno G, Fioravanti D, Procoli A, et al. (2012) Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 14(7): 841-850.
10. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, et al. (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81: 1009-1016.
11. Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, et al. (2012) Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14(4): 483-493.
12. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137(2): 305-310.
13. Li XD, Xu B, Wu J, Ji M, Xu BH, et al. (2012) Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol 14(2): 102-108.
14. Jä kel CE, Hauser S, Rogenhofer S, Mü ller SC, Brossart P, et al. (2012) Clinical studies applying cytokine induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol 2012: 473245.
15. Ma Y, Xu YC, Tang L, Zhang Z, Wang J, et al. (2011) Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 1(1): 11.
16. Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, et al. (2014) Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis. World J Gastroenterol 20(4): 1095-1106.
17. Li H, Wang C, Yu J, Cao S, Wei F, et al. (2009) Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11(8): 1076-1083.
18. Mo C, Gao J, Wang J, Huang Y, Wu X, et al. (2005) Clinical efficacy of DCactivated and cytokine-induced killer cells combined with chemotherapy in treatment of advanced lung cancer. Chinese J Cancer Biotherapy 17(4): 419- 423. doi: 10. 3872/j. issn. 1007-385X. 2010. 04. 011.
19. Peng D, Li J, Yuan J, Liu Y, Yu W, et al. (2012) Efficacy and safety of autologous DC and CIK cells cominedPemetrexed in the treatment of elderly patients with non-small cell lung cancer. Chinese J Immunol 28(7): 648-652. doi: 10.3969/ j.issn.1000-484X.2012. 07.017.
20. Sheng CH, Bao F, Xu S, Chang CY (2011) Clinical research on chemotherapy combined with dendritic cell-cytokine induced killer cells for non-small cell lung cancer. Journal of Practical Oncology 26(5): 503-506.
21. Shi SB, Ma TH, Li CH, Tang XY (2011) Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 98(3): 314-319.
22. Zhong R, Teng J, Han B, Zhong H (2011) Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60(10): 1497-1502.
23. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1-12.
24. Shepherd FA, Douillard JY, Blumenschein GR Jr (2011) Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol 6(10): 1763-1773.
25. Arens R, Schoenberger SP (2010) Plasticity in programming of effector and memory CD8 T-cell formation. Immunological Reviews 235: 190-205.
26. Mucida D, Cheroutre H (2010) The many face-lifts of CD4 T helper cells. Advances in Immunology 107: 139-152.
27. Neurath MF, Finotto S, Glimcher LH (2002) The role of Th1/Th2 polarization in mucosal immunity. Nature Medicine 8: 567-573.
28. Gallimore A, Godkin A (2008) Regulatory T cells and tumor immunity observations in mice and men. Immunology 123: 157-163.
29. Yu J, Zhang W, Jiang H, Li H, Cao S, et al. (2008) CD4 +T cells in CIKs (CD4+ CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biother Radio pharm 23(3): 342-354.
30. Li R, Wang C, Liu L, Du C, Cao S, et al. (2012) Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 61(11): 2125-2133.
31. Xu Y, Xu D, Zhang N, Chen F, Liu J (2011) Observation of Chemotherapy Combined with Cytokine-induced Killer Cells and Dendritic Cells in Patients with the Advanced Non-Small Cell Lung Cancer. Prac J Cancer 25(2): 163-166.
32. Xu Y, Xu D, Zhang N, Chen F, Zhang G, et al. (2011) Effection of NP concurrent chemotherapy radiotherapy and sequential adoptive immunity cell for locally advanced non-small cell lung cancer. Chinese J Cancer Prev Treat 18(13): 1032-1035.
33. Yang L, Ren B, Li H, Yu J, Cao S, et al. (2013) Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62(1): 65-73.
34. You Z, Su X, Liu Y (2012) Observation on Clinical Efficacy of DC-CIK Biotherapy Auxiliary Interventional Chemotherapy on Central Non-Small-Cell Lung Carcinoma. Anti-tumor Phar 2(3): 193-196. doi: 10.3969/j.issn.2095- 1264.2012.03.010.
35. Yuan J, Peng D, Li J (2011) Clinical effects of administering dendritic cells and cytokine induced killer cells combined with chemotherapy in the treatment of advanced non-small cell lung cancer. J Clin Pulmonary Med 16(12): 1910-1911.
36. Zhang J, Mao G, Han Y, Yang X, Feng H, et al. (2012) The clinical effects of DC-CIK cells combined with chemotherapy in the treatment of advanced NSCLC. Chin Ger J Clin Oncol 11(2): 67-71.
37. Zhong R, Han B, Zhong H, Gong L, Sha H, et al. (2008) Dendritic cells immunotherapy combined with chemotherapy inhibits postoperative recurrence and metastasis in stage IB of NSCLC after radical surgery. China Oncol 18(10): 760-764.
38. Zheng FC, Zhang XY, Feng HZ, Chen J, Sun Y, et al. (2012) Clinical Study of Stereotactic Conformal Body γ-knife Combined with Adoptive Immunotherapy (Dendritic Cell and Cytokine-induced Killer Cell) in the Treatment for Advanced Non-small Cell Lung Cancer. Journal of Chinese Oncology 18(11): 815-818.
39. Wang YY, Wang YS, Liu T, Yang K, Yang GQ, et al. (2013) Efficacy study of Cyber Knife stereotactic radio surgery combined with CIK cell immunotherapy for advanced refractory lung cancer. Exp Ther Med 5(2): 453-456.
40. Wolchok JD, Hoos A, O'DayS, Weber JS, Hamid O, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412-7420.
41. McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA (2013) Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother 62(3): 529-539.